Overview Dividends

(APLT) Applied Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03828A1016

Drug Candidate, Phase 3, Galactosemia, Cardiomyopathy, Neuropathy

Biotechnology
Market Cap in USD: 17m
IPO / Inception: 2019-05-14
Return 12m vs S&P 500: -88.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of APLT over the last years for every Quarter: "2020-12": -1.06, "2021-03": -1, "2021-06": -0.99, "2021-09": -1.09, "2021-12": -1.04, "2022-03": -0.88, "2022-06": -0.8, "2022-09": -0.4, "2022-12": -0.16, "2023-03": -0.18, "2023-06": -0.37, "2023-09": -0.47, "2023-12": -0.34, "2024-03": -0.67, "2024-06": 0.02, "2024-09": -0.48, "2024-12": 0.33, "2025-03": 0.3281, "2025-06": -0.15, "2025-09": -0.13,
EPS CAGR: 139.95%
EPS Trend: 70.7%
Last SUE: 0.03
Qual. Beats: 0

Revenue

Revenue of APLT over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 10.66, 2023-06: 0, 2023-09: 0, 2023-12: -0.667, 2024-03: 0.19, 2024-06: 0.144, 2024-09: 0.122, 2024-12: 0, 2025-03: -0.001, 2025-06: 0, 2025-09: 1,
Rev. CAGR: 12.92%
Rev. Trend: -0.5%
Last SUE: 0.22
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 156%
Value at Risk 5%th 170%
Relative Tail Risk -33.74%
Reward TTM
Sharpe Ratio -0.06
Alpha -111.74
CAGR/Max DD -0.48
Character TTM
Hurst Exponent 0.524
Beta 1.479
Beta Downside 2.087
Drawdowns 3y
Max DD 98.87%
Mean DD 45.79%
Median DD 29.71%

Description: APLT Applied Therapeutics December 22, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) is a clinical-stage biotech focused on novel therapies for high-unmet-need diseases in the U.S., with its lead candidate AT-007 having completed Phase 3 in healthy adults for galactosemia and now advancing in pediatric studies and additional rare-enzyme indications.

Key operational metrics and sector context: (1) APLT reported approximately $45 million of cash and short-term investments in its most recent 10-Q, giving it runway through late 2025 under current burn rates; (2) The global rare-disease drug market is projected to surpass $300 billion by 2030, providing a sizable addressable market for AT-007 and related pipelines; (3) Diabetic cardiomyopathy, the target of AT-001 (Phase 3), represents a $10 billion+ therapeutic opportunity as diabetes prevalence rises and cardiometabolic complications drive demand for disease-modifying treatments.

For a deeper quantitative assessment, you may find ValueRay’s platform useful.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-18.1m TTM) > 0 and > 6% of Revenue (6% = 59.9k TTM)
FCFTA -2.53 (>2.0%) and ΔFCFTA -175.9pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -124.9% (prev 56.40%; Δ -181.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -2.53 (>3.0%) and CFO -86.8m <= Net Income -18.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (145.6m) change vs 12m ago 0.84% (target <= -2.0% for YES)
Gross Margin -1678 % (prev -177.7%; Δ -1500 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.42% (prev 9.38%; Δ -7.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -1.22 (EBITDA TTM -67.5m / Interest Expense TTM -82.5m) >= 6 (WARN >= 3)

Altman Z'' -89.31

(A) -0.04 = (Total Current Assets 31.7m - Total Current Liabilities 32.9m) / Total Assets 34.4m
(B) -18.51 = Retained Earnings (Balance) -636.4m / Total Assets 34.4m
warn (B) unusual magnitude: -18.51 — check mapping/units
(C) -1.43 = EBIT TTM -100.6m / Avg Total Assets 70.5m
(D) -18.21 = Book Value of Equity -636.3m / Total Liabilities 34.9m
Total Rating: -89.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.98

1. Piotroski 1.0pt
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity -4.46
5. Debt/Ebitda 0.14
7. RoE -65.63%
8. Rev. Trend -0.51%
9. EPS Trend 70.74%

What is the price of APLT shares?

As of December 25, 2025, the stock is trading at USD 0.12 with a total of 35,004,309 shares traded.
Over the past week, the price has changed by -3.83%, over one month by -55.32%, over three months by -75.20% and over the past year by -86.45%.

Is APLT a buy, sell or hold?

Applied Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy APLT.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the APLT price?

Issuer Target Up/Down from current
Wallstreet Target Price 0.3 108.3%
Analysts Target Price 0.3 108.3%
ValueRay Target Price 0.1 -25%

APLT Fundamental Data Overview December 19, 2025

Market Cap USD = 17.3m (17.3m USD * 1.0 USD.USD)
P/S = 17.3161
P/B = 7.7151
Beta = 2.0
Revenue TTM = 999.0k USD
EBIT TTM = -100.6m USD
EBITDA TTM = -67.5m USD
Long Term Debt = 2.50m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 467.0k USD (from shortTermDebt, last quarter)
Debt = 2.50m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.45m USD (from netDebt column, last quarter)
Enterprise Value = 7.87m USD (17.3m + Debt 2.50m - CCE 11.9m)
Interest Coverage Ratio = -1.22 (Ebit TTM -100.6m / Interest Expense TTM -82.5m)
FCF Yield = -1103 % (FCF TTM -86.8m / Enterprise Value 7.87m)
FCF Margin = -8693 % (FCF TTM -86.8m / Revenue TTM 999.0k)
Net Margin = -1816 % (Net Income TTM -18.1m / Revenue TTM 999.0k)
Gross Margin = -1678 % ((Revenue TTM 999.0k - Cost of Revenue TTM 17.8m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev none%)
Tobins Q-Ratio = 0.23 (Enterprise Value 7.87m / Total Assets 34.4m)
Interest Expense / Debt = 28.84% (Interest Expense 721.0k / Debt 2.50m)
Taxrate = 21.0% (US default 21%)
NOPAT = -79.5m (EBIT -100.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.96 (Total Current Assets 31.7m / Total Current Liabilities 32.9m)
Debt / Equity = -4.46 (negative equity) (Debt 2.50m / totalStockholderEquity, last quarter -561.0k)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -9.45m / EBITDA -67.5m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -9.45m / FCF TTM -86.8m)
Total Stockholder Equity = 27.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.77% (Net Income -18.1m / Total Assets 34.4m)
RoE = -65.63% (Net Income TTM -18.1m / Total Stockholder Equity 27.6m)
RoCE = -333.9% (out of range, set to none) (EBIT -100.6m / Capital Employed (Equity 27.6m + L.T.Debt 2.50m))
RoIC = -287.7% (out of range, set to none) (NOPAT -79.5m / Invested Capital 27.6m)
WACC = 12.90% (E(17.3m)/V(19.8m) * Re(11.47%) + D(2.50m)/V(19.8m) * Rd(28.84%) * (1-Tc(0.21)))
Discount Rate = 11.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.45%
Fair Price DCF = unknown (Cash Flow -86.8m)
EPS Correlation: 70.74 | EPS CAGR: 139.9% | SUE: 0.03 | # QB: 0
Revenue Correlation: -0.51 | Revenue CAGR: 12.92% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.045 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.40 | Chg30d=+0.137 | Revisions Net=+3 | Growth EPS=+25.9% | Growth Revenue=+25.0%

Additional Sources for APLT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle